AR037627A1 - Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamento - Google Patents

Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamento

Info

Publication number
AR037627A1
AR037627A1 ARP020104674A ARP020104674A AR037627A1 AR 037627 A1 AR037627 A1 AR 037627A1 AR P020104674 A ARP020104674 A AR P020104674A AR P020104674 A ARP020104674 A AR P020104674A AR 037627 A1 AR037627 A1 AR 037627A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
headache
weight
manufacture
oral administration
Prior art date
Application number
ARP020104674A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR037627A1 publication Critical patent/AR037627A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Una composición farmacéutica en forma de dosificación sólida para su administración oral, capaz de una rápida desintegración y dispersión dentro del tracto gastrointestinal, que comprende un compuesto que actúa como agonista del receptor 5HT1 o uno de sus derivados farmacéuticamente aceptable como ingrediente activo, en la que más de del 70% preferentemente más de 80%, más preferentemente más del 90% del ingrediente activo se disuelve en fluido gástrico simulado (SGF) durante cinco minutos en un aparato USPII de 10 rpm de velocidad de discriminación de las paletas. El uso de dicha composición farmacéutica para la fabricación de un medicamento para tratar estados asociados al dolor cefálico tal como dolor de cabeza en racimos, hemicránea paroxistica crónica, dolor de cabeza asociado a trastornos vasculares, dolor de cabeza asociado a substancias o a su supresión, dolor de cabeza por efecto rebote, dolor de cabeza de tensión y, en particular migrana. Uso de un componente básico de una pareja efervescente que comprende de 5 a 50% en peso, un desintegrante que comprende de 0,5 a 10% en peso, y una carga insoluble que comprende de alrededor de 30 a 99% en peso que incluye un agente de imbibición que él mismo comprende de alrededor de 1 a alrededor de 99% en peso, basado en el peso en seco de la forma de dosificación, para la preparación de la composición farmacéutica. Reivindicación 12: una composición según una cualquiera de las reivindicaciones 1 a 11, caracterizada por que el agonista del receptor 5HT1, es sumatriptan o uno de sus derivados farmacéuticos aceptable.
ARP020104674A 2001-12-05 2002-12-03 Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamento AR037627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0129117.8A GB0129117D0 (en) 2001-12-05 2001-12-05 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
AR037627A1 true AR037627A1 (es) 2004-11-17

Family

ID=9927051

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104674A AR037627A1 (es) 2001-12-05 2002-12-03 Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamento

Country Status (29)

Country Link
US (1) US20050032867A1 (es)
EP (2) EP1450770B1 (es)
JP (1) JP3699969B2 (es)
KR (1) KR100591237B1 (es)
CN (1) CN1289069C (es)
AR (1) AR037627A1 (es)
AT (1) ATE291900T1 (es)
AU (1) AU2002358602B2 (es)
BR (1) BR0214497A (es)
CA (1) CA2469019C (es)
CO (1) CO5580741A2 (es)
DE (1) DE60203537T2 (es)
ES (1) ES2236608T3 (es)
FI (1) FI20022128A (es)
GB (1) GB0129117D0 (es)
HK (1) HK1069111A1 (es)
HU (1) HU229313B1 (es)
IL (1) IL161997A (es)
IS (1) IS2481B (es)
MX (1) MXPA04005420A (es)
MY (1) MY129314A (es)
NO (1) NO329896B1 (es)
NZ (1) NZ532829A (es)
PL (1) PL194702B1 (es)
PT (1) PT1450770E (es)
RU (1) RU2285526C2 (es)
TW (1) TWI240638B (es)
WO (1) WO2003047552A2 (es)
ZA (1) ZA200403849B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
JP2006522790A (ja) * 2003-04-11 2006-10-05 ファイザー・インク エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物
WO2004110492A2 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition comprising triptans and nsaids
EP1750677B1 (en) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
CA2584957C (en) 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CA2629904C (en) * 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20070259040A1 (en) * 2006-05-01 2007-11-08 Cherukuri S R Novel triptan formulations and methods for making them
WO2008039358A2 (en) * 2006-09-30 2008-04-03 Capricorn Pharma Inc. Resin-complex granulation for water-soluble drugs and associated methods
WO2011067667A2 (en) 2009-12-02 2011-06-09 Eurand Pharmaceuticals Limited Fexofenadine microcapsules and compositions containing them
US11364225B2 (en) 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468504A (en) * 1990-12-21 1995-11-21 Laboratoires Glaxo S.A. Effervescent pharmaceutical compositions
GB9027827D0 (en) * 1990-12-21 1991-02-13 Glaxo Laboratoires Pharmaceutical compositions
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
AU2640599A (en) * 1998-02-26 1999-09-15 Banyu Pharmaceutical Co., Ltd. An orally disintegrating composition and its manufacturing method
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
EP1246668B1 (en) * 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
KR20010107754A (ko) * 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법
US20030008005A1 (en) * 2001-07-05 2003-01-09 R.T. Alamo Ventures, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine

Also Published As

Publication number Publication date
MXPA04005420A (es) 2004-10-11
MY129314A (en) 2007-03-30
IS7293A (is) 2004-06-03
PL370669A1 (en) 2005-05-30
TW200304384A (en) 2003-10-01
TWI240638B (en) 2005-10-01
EP1450770A2 (en) 2004-09-01
AU2002358602A1 (en) 2003-06-17
CN1610539A (zh) 2005-04-27
NO329896B1 (no) 2011-01-24
HUP0402178A3 (en) 2011-05-30
JP3699969B2 (ja) 2005-09-28
HK1069111A1 (en) 2005-05-13
KR100591237B1 (ko) 2006-06-19
US20050032867A1 (en) 2005-02-10
RU2285526C2 (ru) 2006-10-20
WO2003047552A3 (en) 2003-09-25
NZ532829A (en) 2005-05-27
IL161997A (en) 2005-12-18
EP1450770B1 (en) 2005-03-30
CA2469019A1 (en) 2003-06-12
NO20025805D0 (no) 2002-12-03
AU2002358602B2 (en) 2005-05-26
CO5580741A2 (es) 2005-11-30
FI20022128A (fi) 2003-06-06
ZA200403849B (en) 2005-10-26
IS2481B (is) 2008-12-15
DE60203537D1 (de) 2005-05-04
FI20022128A0 (fi) 2002-12-03
CA2469019C (en) 2005-09-13
BR0214497A (pt) 2004-10-19
DE60203537T2 (de) 2005-09-15
WO2003047552A2 (en) 2003-06-12
EP1527773A1 (en) 2005-05-04
GB0129117D0 (en) 2002-01-23
KR20050044720A (ko) 2005-05-12
PT1450770E (pt) 2005-08-31
ATE291900T1 (de) 2005-04-15
IL161997A0 (en) 2005-11-20
HU229313B1 (en) 2013-10-28
JP2005515991A (ja) 2005-06-02
NO20025805L (no) 2003-06-06
PL194702B1 (pl) 2007-06-29
CN1289069C (zh) 2006-12-13
ES2236608T3 (es) 2005-07-16
HUP0402178A2 (hu) 2005-02-28
RU2004120292A (ru) 2005-04-10

Similar Documents

Publication Publication Date Title
AR037627A1 (es) Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamento
JP2023134518A (ja) 透過性増強された医薬組成物
JP2023052143A (ja) 送達増強エピネフリン組成物
EA201190012A1 (ru) Твердые лекарственные формы бендамустина
ES2282062T1 (es) Composicion farmaceutica que contiene irbesartan.
JPWO2002096406A1 (ja) 医薬組成物
IT1282352B1 (it) Composizione farmaceutica, in particolare essiccata mediante congelamento, per somministrazione orale di ondansetron e metodo per
ES2520990T3 (es) Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina
CA2535803A1 (en) Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
JP4106232B2 (ja) 医薬組成物
JP2005154437A (ja) トラニラスト含有医薬組成物
JP2024507991A (ja) 激越を処置するための方法及び組成物
US20080242717A1 (en) Methods for treating benign prostatic hyperplasia
JP4632687B2 (ja) 点鼻剤
ES2365409T3 (es) Compuestos de dihidropiridina para enfermedades neurodegenerativas y demencia.
KR20200131913A (ko) 플루르비프로펜을 포함하는 약학적 조성물
CN105250316A (zh) 一种含二联苯酚的抗癫痫药物组合
ES2443968T3 (es) Composiciones farmacéuticas de olmesartán
JP5054966B2 (ja) 固形製剤
BR112020012157A2 (pt) composição farmacêutica oral de um antagonista de nk-1
US7842702B2 (en) Treatment for irritable bowel syndrome
JP5329866B2 (ja) 医薬組成物及び関節障害の予防治療剤
AR118056A2 (es) Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y uso de las mismas
WO2023187599A1 (en) Methods and bioavailable highly permeable compounds for the treatment of viral diseases
PT1653963E (pt) Composição farmacêutica nasal de piribedil

Legal Events

Date Code Title Description
FB Suspension of granting procedure